Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 401–500 of 748
The Future of Deep Venous Thrombosis and Post-thrombotic Syndrome in 2020
Comerota, A. J. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2011.012s08 · Cited by 10
Ximelagatran for the secondary prevention of venous thromboembolism
Schulman, S., Lundström, T., Wåhlander, K., Clason, S. B., Eriksson, H., & for the THRIVE III Investigators (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-04-0228 · Cited by 10
“7 events/100 patient-years for standardintensity warfarin (1), and 1.”
BackgroundImproving Anticoagulation Measurement: Novel Warfarin Composite Measure
Razouki, Z. A., Burgess, J. F., Ozonoff, A., Zhao, S., Berlowitz, D. R., & Rose, A. J. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.001789 · Cited by 10
Keller, K., Münzel, T. F., Hobohm, L., & Ostad, M. A. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.075 · Cited by 10
Warfarin: balancing the benefits and harms
Borosak, M. (2004) · Australian Prescriber · doi:10.18773/austprescr.2004.074 · Cited by 10
Venous Thromboembolism Guidebook
Gelfand, E. V., Piazza, G., & Goldhaber, S. Z. (2002) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/00132577-200203000-00006 · Cited by 10
A Silent Killer—Often Preventable
Futterman, L. G., & Lemberg, L. (2004) · American Journal of Critical Care · doi:10.4037/ajcc2004.13.5.431 · Cited by 10
Treatment of ANCA-Associated Vasculitis
Santana, A. N. C., Antunes, T., & Barbas, C. S. V. (2007) · JAMA · doi:10.1001/jama.298.23.2739-a · Cited by 10
Establishing an Optimal Therapeutic Range for Coumarins
O'Donnell, M. J., & Hirsh, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.588 · Cited by 10
Safety of anticoagulant treatment in cancer patients
Wilts, I. T., Bleker, S. M., van Es, N., Buller, H. R., Nisio, M. D., & Kamphuisen, P. W. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1052739 · Cited by 9
“0, although evidence for this range is lacking [42].”
BackgroundVenous thromboembolism in centenarians: Findings from the RIETE registry
Lacruz, B., Tiberio, G., Núñez, M. J., López‐Jiménez, L., Riera‐Mestre, A., Tiraferri, E., Verhamme, P. B., Mazzolai, L., González, J., & Monréal, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.07.025 · Cited by 12
Exercise and Air-Travel–Induced Alterations in Blood Hemostasis
Kupchak, B. R. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1670640 · Cited by 9
Management of venous thromboembolism
de Moerloose, P., Samama, C. M., & Motte, S. (2006) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03022255 · Cited by 9
Optimal duration of anticoagulation in patients with venous thromboembolism.
Prandoni, P., Piovella, C., Spiezia, L., Valle, F. D., & Pesavento, R. (2011) · PubMed Central · Cited by 13
Chen, W. T., White, C. M., Phung, O. J., Kluger, J., Ashaye, A. O., Sobieraj, D. M., Makanji, S. S., Tongbram, V., Baker, W. L., & Coleman, C. I. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02694.x · Cited by 9
Isolated Calf Vein Thrombosis Should Be Treated With Anticoagulation
Lohr, J. M., & Fellner, A. N. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.010 · Cited by 9
Bauer, K. A. (2011) · JAMA · doi:10.1001/jama.2011.361 · Cited by 11
The Role of Ximelagatran in the Treatment of Venous Thromboembolism
Schulman, S. (2005) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000083080 · Cited by 9
“Low-intensity warfarin was found to be significantly more effective than placebo in reducing the risk of recurrent VTE events (2.6 and 7.2/100 person-years, respectively) and was associated with a 48p reduction in the composite end point of recurrent VTE, major bleeding and death.These results support a role for low-i…”
ResultInfluentialEdwards, F., Arkell, P., Fong, A. Y. Y., Roberts, L. M., Gendy, D., Wong, C. S.-H., Ngu, J. C. Y., Tiong, L. L., Bibi, F. M. S., Lai, L. Y. H., et al. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1017-6 · Cited by 9
Fox, K. A. A., White, H. D., Gersh, B. J., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00018-1 · Cited by 11
Ximelagatran: A clinical perspective
Boos, C. J., Hinton, A., & Lip, G. Y. H. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.02.005 · Cited by 9
Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome
Crowther, M. A. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.011 · Cited by 9
Self-citationIs the current classification of venous thromboembolism acceptable? No
WHITE, H., & Murin, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01075.x · Cited by 9
First Episode and Recurrent Venous Thromboembolism: Who is Identifiably at Risk?
Liem, T. K., & DeLoughery, T. G. (2008) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2008.05.006 · Cited by 9
Kearon, C. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.06.003 · Cited by 9
“5) in 4 studies,(20,23,24,74) and to a low intensity in 2 studies.(17,23) Four studies compared indefinite therapy with a finite (short) course of warfarin,(17,20,24,74) and 1 study compared standardintensity with low-intensity anticoagulation.”
BackgroundResultInfluentialSelf-citationNakamura, M., Tamaru, S., Hirooka, S., Hirayama, A., Tsuji, A., Hirata, M., Munemasa, M., Nakagawa, I., Toshima, M., Shimokawa, H., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0158 · Cited by 8
Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study
Ekblom, K., Hultdin, J., Carlberg, B., & STRAND, T. (2005) · Thrombosis Journal · doi:10.1186/1477-9560-3-20 · Cited by 8
Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery
Najibi, B., Tabib, A., Dalili, M., Baghaei, R., & Poopak, B. (2015) · Research in Cardiovascular Medicine · doi:10.5812/cardiovascmed.27963v2 · Cited by 8
“Nonetheless, warfarin anticoagulant therapy is difficult to manage due to the narrow therapeutic index and wide variability of dose response among individuals (1-3).”
BackgroundInfluentialLong-Term Anticoagulation Prophylaxis Following Acute Thromboembolism
Hyers, T. M. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.03.011 · Cited by 8
Update in the Treatment of Venous Thromboembolism
Garcia, D. A., & Spyropoulos, A. C. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2008-1047561 · Cited by 8
Clinical Probability Tools for Deep Venous Thrombosis, Pulmonary Embolism, and Bleeding
Harder, E. M., Desai, O., & Marshall, P. S. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.001 · Cited by 8
Schnegg-Kaufmann, A. S., Calzavarini, S., Limacher, A., Méan, M., Righini, M., Staub, D., Beer, J., Frauchiger, B., Osterwalder, J. J., Kucher, N., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14365 · Cited by 9
Agnelli, G. (2004) · Drugs · doi:10.2165/00003495-200464001-00007 · Cited by 8
Bergqvist, D. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00298.x · Cited by 8
Secondary prevention of venous thromboembolism
Schulman, S., & Douketis, J. D. (2013) · BMJ · doi:10.1136/bmj.f5440 · Cited by 8
Secondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All
Blondon, M., & Bounameaux, H. (2015) · Circulation · doi:10.1161/circulationaha.115.019310 · Cited by 10
Diagnosis and Anticoagulant Treatment
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M. M., Fletcher, J. M., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840n · Cited by 8
“However, in a direct comparison between conventional anticoagulation and low-dose warfarin, the former proved to be more effective and equally safe.(75) Indeed, in this study involving 738 patients with unprovoked proximal DVT or PE, the incidence of recurrence over a 2 to 4 years of follow-up increased from 2% in the…”
ResultSelf-citationLiu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
Update on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 9
“No significant differences were observed in major hemorrhage or overall bleeding.(40) Target INRs above 3.”
BackgroundNon-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism
Bauersachs, R. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.022 · Cited by 7
“Although the placebo-controlled study demonstrated better efficacy of the low-dose warfarin regimen versus placebo [36], comparison with the standard dose revealed that low-dose warfarin was less effective for the long-term prevention of VTE and was associated with a similar risk of clinically important bleeding event…”
Bauersachs, R. M., & Breddin, H. K. (2004) · Der Internist · doi:10.1007/s00108-004-1161-3 · Cited by 7
“sen Patienten das Risiko für schwere Blutungen genauso hoch zu sein scheint wie bei der Standardbehandlung mit einer INR von 2,0–3,0 [16].”
BackgroundIs there a role for low-dose DOACs as prophylaxis?
Cohen, A. T., & Hunt, B. J. (2019) · Hematology · doi:10.1182/hematology.2019000026 · Cited by 7
Swan, D., Seiffge, D. J., & Thachil, J. V. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09775-7 · Cited by 7
Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment
Gaboreau, Y., Zenati, N., Vermorel, C., Imbert, P., Bosson, J., & Pernod, G. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1668-4 · Cited by 7
Stroke Prevention in Atrial Fibrillation
Katsnelson, M. J., Koch, S., & Rundek, T. (2010) · Journal of Atrial Fibrillation · doi:10.4022/jafib.v2i2.584 · Cited by 8
Rosero, H. A. M., Osorio, S., Méndez, D. P. G., Botero, J. D., Cataño, J. U., Tobón, L. I., Mejía, F. A., Isaza, F. G., Bedoya, M., & Aguirre, D. C. I. (2016) · Acta Médica Colombiana · doi:10.36104/amc.2016.524 · Cited by 17
Extended anticoagulation for unprovoked venous thromboembolism
Castellucci, L. A., de Wit, K., Garcia, D. A., Ortel, T. L., & Gal, G. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12121 · Cited by 7
Siragusa, S., Caramazza, D., & Malato, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07578.x · Cited by 7
“The rates of recurrent VTE in these trials varied depending on whether enrolled patients had idiopathic DVT (Kearon et al, 1999; Pinede et al, 2001; Kearon et al, 2003; Agnelli et al, 2001, 2003; Ridker et al, 2003), provoked DVT (Kearon et al, 2004) or the presence of a permanent risk factor for…”
BackgroundLow-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly
Pineo, G. F., & Hull, R. D. (2005) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960501100102 · Cited by 7
Oral Anticoagulation: Preparing for Change
Nutescu, E. A., Spyropoulos, A. C., & Cranmer, K. W. (2004) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70033-x · Cited by 7
Prise en charge des affections veineuses chroniques des membres inférieurs
Nicolaides, A. N., Allegra, C., Bergan, J. J., Bradbury, A. W., Cairols, M. A., Carpentier, P., Comerota, A. J., Delis, C., Eklöf, B., Fassiadis, N., et al. (2009) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(09)75325-9 · Cited by 7
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00016-6 · Cited by 8
Venous Thromboembolism Guidebook, Fourth Edition
Gelfand, E. V., Piazza, G., & Goldhaber, S. Z. (2003) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000099520.72099.bd · Cited by 7
Mars or Venus — Is Sex a Risk Factor for Recurrent Venous Thromboembolism?
Elliott, C. G., & Rubin, L. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048079 · Cited by 7
New Therapeutic Approaches in Pulmonary Embolism
Schellong, S., & Schmidt, B. (2003) · Respiration · doi:10.1159/000075198 · Cited by 7
Acute pulmonary embolism advances in treatment.
Gupta, S., & Gupta, B. M. M. (2008) · PubMed · Cited by 6
Folkerts, K., Broughton, J., Sheikh, U., & Mckaig, S. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1658589 · Cited by 8
Alam, U., Ali, M. A., Ansab, M., Rath, S., Khattak, F., Bacha, Z., Siddiqui, H. T., Sajjad, F., Afridi, A., Afridi, Z., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04388-1 · Cited by 6
“…warfarin, which was unable to establish this balance, recent randomized controlled trials have revealed that reduced-dose apixaban and rivaroxaban can provide an acceptable risk–benefit ratio compared to placebo, aspirin, and full-dose regimens (Kearon et al. 2003; Vasanthamohan et al. 2021 Sep).”
Kuhli-Hattenbach, C., Miesbach, W., Scharrer, I., & Kuhli-Hattenbach, C. (2011) · Der Ophthalmologe · doi:10.1007/s00347-010-2289-2 · Cited by 6
Sista, A. K. (2014) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2014.02.011 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Iñurrieta, A., Pedrajas, J. M., Núñez, M. J., López‐Jiménez, L., Velo-García, A., García, J., Lecumberri, R., Jiménez, D., Pons, I., Monréal, M., et al. (2018) · TH Open · doi:10.1055/s-0038-1676359 · Cited by 9
Spyropoulos, A. C., & Haire, W. D. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000011378.16223.e4 · Cited by 6
Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V
Bhogal, S. S., Mukherjee, D., Banerjee, S., Islam, A. M., Daggubati, R. B., & Paul, T. K. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.10.003 · Cited by 6
Protein S: A multifunctional anticoagulant
Dorsey, A. W., Pilli, V. S. S., Fried, H. M., & Majumder, R. (2017) · Biomedical Research and Clinical Practice · doi:10.15761/brcp.1000151 · Cited by 6
“Acquired PS deficiency accounts for a small number of cases that result from advanced age, warfarin use, pregnancy, and liver disease [12,13,21-23].”
Ginsberg, J. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00081-6 · Cited by 6
Self-citationSantana, A. N. C., Ab’Saber, A. M., Teodoro, W. R., Capelozzi, V. L., & Barbas, C. S. V. (2010) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132010000600009 · Cited by 6
Schellong, S., Bounameaux, H., & Buller, H. R. (2009) · doi:10.1093/med/9780199566990.003.037 · Cited by 7
Duration of anticoagulant therapy for venous thromboembolism
Raju, N. C., Hirsh, J., & Eikelboom, J. W. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02629.x · Cited by 6
aguda, G. D. T. D. L. S. P. L. G. D. L. E. 2. S. E. D. Y. T. D. L. E. P., aguda, R. E. P. L. G. D. L. E. 2. S. E. D. Y. T. D. L. E. P., & Comité de Guías de la, S. E. C. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.11.006 · Cited by 7
Warfarina versus acenocumarol en alcanzar niveles terapéuticos en una población ambulatoria
Raúl Romero, L., Pablo Vargas, M., & Víctor Letelier, A. (2009) · Revista chilena de cardiología · doi:10.4067/s0718-85602009000300006 · Cited by 5
Jerjes-Sánchez, C., González, J. J. E., Sandoval, J., Gutiérrez‐Fajardo, P., Seoane, M., Ramírez‐Rivera, A., Pulido, T., Beltrán, M., Santos-Ordóñez, E., Bautista, E., et al. (2004) · Revista Portuguesa de Pneumologia · Cited by 8
Harenberg, J., Bauersachs, R. M., Diehm, C., Lawall, H., Burkhardt, H., Gerlach, H. E., Darius, H., Völler, H., Rabe, E., & Wehling, M. (2010) · Der Internist · doi:10.1007/s00108-010-2702-6 · Cited by 5
Review Article: Venous Thromboembolism after Total Joint Replacement
Leung, K., Chiu, P., Yan, C., Ng, F., & Ping Keung, C. H. A. N. (2013) · Journal of orthopaedic surgery · doi:10.1177/230949901302100318 · Cited by 5
Duration of Anticoagulation for Venous Thromboembolic Events
Smilowitz, N. R., Mega, J. L., & Berger, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010456 · Cited by 6
Association between apolipoprotein E genotype and warfarin response during initial anticoagulation
He, S., Zhang, H., Cao, Y., Nian, F., Chen, H., Chen, W., Auchoybur, M. L., Yin, L., Tao, Z., Tang, S., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.095 · Cited by 5
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
Freischlag, J. A., & Heller, J. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1560-6.00065-2 · Cited by 5
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Couturaud, F. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.04.017 · Cited by 7
Screening Feature Genes of Venous Thromboembolism with DNA Microarray
Zhou, T., Zhang, Y., Wu, P., Sun, Q., & Guo, Y. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12557 · Cited by 7
“Previous studies in subjects with VTE indicate that an extended course of anticoagulation will decrease the risk of recurrence (7,8).”
BackgroundSpontaneous subscapular haematoma in a patient using warfarin therapy
Çebiçci, H., Gürbüz, Ş., Günay, N., & Vural, A. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-201042 · Cited by 5
Robin, P., Eddy, M., Sikora, L., Roux, P. L., Carrier, M., Couturaud, F., Planquette, B., Pesavento, R., Rodger, M. A., Salaün, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023939 · Cited by 5
Self-citationMacLehose, R. F., Zakai, N. A., Walker, R. F., Alonso, Á., Adams, T., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12514 · Cited by 5
Orale Antikoagulanzien vom Cumarintyp
Kemkes‐Matthes, B. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617188 · Cited by 5
“(9) 2003, dass eine Langzeit-Prophylaxe mit INR 2,0 bis 3,0 bezüglich des Auftretens thromboembolischer Rezidive einer Lowintensity-Prophylaxe mit Ziel-INR 1,5 bis 1,9 signifikant überlegen ist.”
BackgroundSpotlight on real-world evidence for the treatment of DVT: XALIA
Turpie, A. G. G., & Ageno, W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0488 · Cited by 5
Self-citationMorris, T. A., & Fedullo, P. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00051-1 · Cited by 5
Prevention of thrombosis with warfarin, aspirin, and mechanical methods
Merli, G. J. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80103-6 · Cited by 5
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Tran, H. A., McRae, S. J., & Ginsberg, J. S. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.006 · Cited by 6
Self-citationVenous Thromboembolism Guidebook: Fifth Edition
Piazza, G., & Goldhaber, S. Z. (2006) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/01.hpc.0000243629.32681.b6 · Cited by 6
“4 years, 16 patients in the lowintensity group had recurrent VTE compared with 6 in the conventional-intensity group without any significant difference in the risk of bleeding.(73) In the randomized, controlled Thrombin Inhibitor in Venous Thromboembolism III (THRIVE III), patients were randomly assigned to receive 18…”
BackgroundMethodAgnelli, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00812.x · Cited by 5
Anticoagulation in Acute Pulmonary Embolism
Kelly, J., Rudd, A., Hunt, B. J., & Lewis, R. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1195 · Cited by 5
“0) is associated with an increased likelihood of recurrent PE or DVT and more intense anticoagulation is associated with bleeding [9,49-52].”
BackgroundCardin, T., & Marinelli, A. (2004) · Critical Care Nursing Quarterly · doi:10.1097/00002727-200410000-00002 · Cited by 6
The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
Galanaud, J. ‐., Laroche, J.-P., & Righini, M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.019 · Cited by 5
Liem, T. K., & DeLoughery, T. G. (2011) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2011.11.003 · Cited by 5
Strengths and Limitations of Standards of Care to Guide the Orthopedic Surgeon in VTE Prevention
Friedman, R. J., & Haas, S. K. (2011) · Orthopedics · doi:10.3928/01477447-20101221-25 · Cited by 4
Unusual redo mitral valve replacement for bleeding in Glanzmann thrombasthenia
Garcı́a-Villarreal, O. A., Fernández-Ceseña, E., Solano-Ricardi, M., Aguilar-García, A. L., Vega-Hernández, R., & Angel-Soto, G. D. (2014) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/0218492314539333 · Cited by 4
“0.(6,7) Although the interaction between GT and warfarin is not yet clear, the risk of oral anticoagulant therapy in patients with GT remains unrecognized.”
BackgroundTrujillo‐Santos, J., & Monréal, M. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835463a4 · Cited by 4
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Pharmacogenetics of warfarin treatment for potential clinical application
Rieder, M. J. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0069-6 · Cited by 4
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.